Skip to content

Intracranial pressure (ICP) monitoring in patients with severe brain injury: a multicenter prospective observational study in China

Intracranial pressure (ICP) monitoring in patients with severe brain injury: a multicenter prospective observational study in China - NEPTUNE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070450
Enrollment
Unknown
Registered
2023-04-12
Start date
2023-04-30
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain injury

Interventions

ICP group:N/A
non-ICP group:N/A

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult, no gender limit, aged >=18 years; 2. Acute brain injury due to hemorrhagic causes, including subarachnoid hemorrhage, cerebral hemorrhage, or craniocerebral trauma; 3. When admitted to ICU, Glasgow Coma Scale (GCS) score eye opening =1 point (stimulation did not open eyes), exercise score <=5 points (exercise without compliance), or neurological function deterioration within 48 hours after admission to ICU, GCS score eye opening =1 point (stimulation did not open eyes), exercise score <=5 points (exercise without compliance); 4. Informed consent has been signed.

Exclusion criteria

Exclusion criteria: 1. The brain injury did not reach the corresponding severity degree and was not admitted to the intensive care unit; 2. Patients with craniocerebral injury caused by intracranial infection, cerebral ischemia, congenital malformations, autoimmune encephalitis, and craniocerebral tumors; 3. Complicated with systemic malignant tumor, acute stage or functional decompensation of major systemic and organ diseases; 4. Patients of childbearing age who do not use effective contraception and have no record of negative pregnancy tests; 5. Undergoing experimental drug or device testing.

Design outcomes

Primary

MeasureTime frame
Neurological outcome 6 months after onset;Mortality 6 months after onset;

Secondary

MeasureTime frame
Neurological outcome in ICU;Neurological outcome at discharge;Mortality in ICU;Mortality at discharge;

Countries

China

Contacts

Public ContactGao Guoyi

Beijing Tiantan Hospital, Capital Medical University

gao3@sina.com+86 13801874393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026